Trump spares drugmakers from tariffs; costs could still go up
- President Donald Trump's administration excluded pharmaceuticals from recent tariffs, giving consumers a temporary reprieve.
- Analysts warned that tariffs could lead to significant price increases for generic drugs, potentially costing patients an extra $8,000 to $10,000 for cancer treatments.
- PhRMA supports Trump's goal of boosting American manufacturing, as experts warned that tariffs could raise drug prices significantly.
- Patients for Affordable Drugs expressed concern that higher costs could worsen affordability for drugs already inaccessible to many Americans.
15 Articles
15 Articles
Customs duties: "Can have unpredictable consequences" – the new danger for the supply of medicines
Trump's tariffs hit Germany's export nation to the mark. This also applies especially to local pharmaceutical companies. Although medications have so far been excluded from the new tariffs, even with the exception of those that German patients could soon feel.
Trump spares drugmakers from tariffs; costs could still go up
President Trump spared pharmaceuticals from the opening salvo in his campaign to transform the economy through “reciprocal” tariffs; however, the global drug market may still be hit by reverberations from trade wars. The White House listed pharmaceuticals as exempted from the tariffs in Trump’s order signed Wednesday and set to take effect Saturday. Other exempted…
Coverage Details
Bias Distribution
- 44% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage